JUVÉDERM® VOLUMA® With Lidocaine for Correction of Temple Hollowing in Chinese Population
NCT ID: NCT04891419
Last Updated: 2024-12-12
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
168 participants
INTERVENTIONAL
2021-07-20
2023-11-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JUVÉDERM® VOLUMA® with Lidocaine
Participants will be treated with JUVÉDERM® VOLUMA® with Lidocaine injectable gel in temple. Participants are eligible for touch up treatment
JUVÉDERM® VOLUMA® with Lidocaine
JUVÉDERM® VOLUMA® with Lidocaine injectable gel
Control- No treatment
No treatment is administered. Optional treatment at month 6.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JUVÉDERM® VOLUMA® with Lidocaine
JUVÉDERM® VOLUMA® with Lidocaine injectable gel
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants seeking improvement of temple hollowing
* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in the protocol
* Written informed consent from the participant has been obtained prior to any study-related procedures
* Written documentation has been obtained in accordance with the relevant country and local privacy requirements, where applicable
* Is able to complete effectiveness self-assessments without the use of glasses (contact lens use is acceptable if they will be used for all participant self-assessments)
Exclusion Criteria
* Has experienced trauma to the temple area within 6 months before enrollment or has residual deficiencies, deformities, or scarring
* Temporal arteritis or history of temporal arteritis
* Temporomandibular joint dysfunction or any other jaw issues
* Recurrent temporal headaches such as temporal tendinitis migraine
* Active or recurrent inflammation or infection in either eye
* Tendency to develop hypertrophic scarring
* Active autoimmune disease
* History of anaphylaxis or allergy to lidocaine (or any amide-based anesthetics), HA products, or Streptococcal protein
* Current cutaneous or mucosal inflammatory or infectious processes (e.g. acne, herpes), abscess, an unhealed wound, or a cancerous or precancerous lesion, above the subnasal
* Prior facial reconstructive surgeries, facelift, or browlift as well as surgeries on the temple area (eg, biopsy)
* Fat injection or permanent facial implants anywhere in the face
* Semipermanent soft-tissue filler treatment in the temple or mid-face within 36 months before enrollment
* Temporary dermal filler injections above the subnasale within 12 months before enrollment
* Mesotherapy or cosmetic facial procedures above the subnasale within 6 months before enrollment (examples of mesotherapy or cosmetic facial procedures are laser, photomodulation, intense pulsed light, radio frequency, dermabrasion, moderate or greater depth chemical peel, or other ablative procedures.
* Injections in the nasolabial fold are acceptable only if done at least 3 months prior to enrollment
* Botulinum toxin treatment above the subnasale within 6 months before enrollment
* Has braces or other orthodontics
* Not eligible for this study if participants have begun using any new over the counter or prescription oral or tropical, anti-wrinkle products above the subnasale within 30 days before enrollment. Participants who have been on a regimen of such products for at least 30 days are eligible for the study if they intend to continue their regimen throughout the study
* Is on a regimen of anti-coagulation therapy (eg, warfarin, clopidogrel)
* Has tattoos, piercings, facial hair, or scars above and including the subnasale that would interfere with visual assessment of the temple
* Females who are pregnant, nursing, or planning a pregnancy
* Plans a significant weight change (more than 10% of body weight) during the study
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Allergan
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ALLERGAN, INC.
Role: STUDY_DIRECTOR
Allergan
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China-Japan Friendship Hospital /ID# 241680
Beijing, Beijing Municipality, China
Beijing Hospital /ID# 233582
Beijing, Beijing Municipality, China
Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 233602
Wuhan, Hubei, China
Nanjing Drum Tower Hospital /ID# 233607
Nanjing, Jiangsu, China
Zhongda Hospital Southeast University /ID# 233604
Nanjing, Jiangsu, China
Shanghai Ninth People's Hospital,Shanghai Jiaotong University School of Medicine /ID# 233571
Shanghai, Shanghai Municipality, China
Shanghai Sixth People's Hospital /ID# 233568
Shanghai, Shanghai Municipality, China
Peking University International Hospital /ID# 242166
Beijing, , China
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1878-701-008
Identifier Type: -
Identifier Source: org_study_id